Reports and Briefs on Central Nervous System

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Report
Report

Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market

In-depth analysis of the epilepsy drug pipeline, including assessment of the clinical and commercial prospects of late-stage agents, unmet market needs, sales forecasts to 2019, and key opinion leader insight.

Published By Datamonitor
12 May 2010 $11400
Buy

Order this report by the 10th September 2010 and receive a 15% discount

To take advantage of this offer enter Promo Code opioid15 when prompted in the checkout

More information

Report
Report

Commercial Insight: Opioids in Australia

In-depth overview and 10 year outlook for currently marketed and pipeline opioid products in Australia, examining both clinical and commercial factors driving product differentiation and uptake.

Published By Datamonitor
20 May 2010 $5700
Buy
Report
Report

Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments

Analysis of the current and future migraine market. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
13 Jul 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt

Analysis of the current and future insomnia market. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
14 Jul 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

Analysis of the current and future moderate to severe chronic nociceptive pain market with sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key brands, generics, and pipeline products.

Published By Datamonitor
20 Aug 2010 $15200
Buy
Report
Report

Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics

Analysis of the future moderate to severe acute pain market with sales forecasts to 2019 across the seven major markets (US, Japan, 5EU) of key brands, generics, and pipeline products.

Published By Datamonitor
01 Nov 2010 $6400
Buy
Report
Report

Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

Analysis of the current and future market for drugs treating depression. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
09 Dec 2010 $6400
Buy
Report
Report

Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized market

Primary research-based analysis of the epilepsy market, based on a survey of 180 neurologists in the US, Japan, and EU. Includes epidemiology, patient segmentation, treatment trends, perception of key brands, and patient outcomes.

Published By Datamonitor
16 Dec 2010 $6400
Buy
Report
Report

Pipeline and Commercial Insight: Parkinson's Disease - Reformulations sustain market growth in the absence of therapeutic breakthroughs

This report provides full analysis of the current and future Parkinson’s disease market, with forecasts to 2019 of current drugs and key pipeline products in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
17 Dec 2010 $6400
Buy
Report
Report

Stakeholder Insight: Major Depressive Disorder - Gaining traction among physicians is crucial in an SSRI-dominated market

Primary research-based analysis of the major depressive disorder market, based on a survey of 180 psychiatrists in the US, Japan, and EU. Includes epidemiology, patient segmentation, treatment trends, perception of key brands, and patient outcomes.

Published By Datamonitor
23 Dec 2010 $6400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.